Home
Home

myelofibrosis

Geron Soars After Study Shows Bone Marrow Drug’s Benefit

Geron Soars After Study Shows Bone Marrow Drug’s Benefit
Bloomberg

Whither Sanofi R&D? Another Setback For An Oncology Drug

Whither Sanofi R&D? Another Setback For An Oncology Drug
Pharmalot

Baxter, Cell Therapeutics announce collaboration to develop pacritinib

Baxter, Cell Therapeutics announce collaboration to develop pacritinib
Yahoo/Fly on the Wall

Geron soars after myelofibrosis drug shows 44% response rate

Geron soars after myelofibrosis drug shows 44% response rate
The Fly on the Wall

Incyte Has First-Mover Advantage

Incyte Has First-Mover Advantage
Motley Fool

Myelofibrosis Battle: Novartis Vs. Sanofi

Myelofibrosis Battle: Novartis Vs. Sanofi
Seeking Alpha

This Biotech Has So Many Reasons to Be Liked

This Biotech Has So Many Reasons to Be Liked
Motley Fool

Is This Myelofibrosis Drug a Blockbuster?

Is This Myelofibrosis Drug a Blockbuster?
Motley Fool

Geron rises on 2Q results and imetelstat update

Geron rises on 2Q results and imetelstat update
Yahoo/AP

Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis

Incyte Drug Jakafi® (ruxolitinib) Improved Overall Survival in Phase III Trial of Patients with Myelofibrosis
Yahoo/BusinessWire